Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents-Reference-Cited by-同舟云学术

Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents

Published:2013 Issue:3 Volume:84 Page:158-165
ISSN:1423-0232
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Bamias Aristotle,Bamia Christine,Zagouri Flora,Kostouros Efthimios,Kakoyianni Konstantina,Rodolakis Alexandros,Vlahos George,Haidopoulos Dimitrios,Thomakos Nikolaos,Antsaklis Aris,Dimopoulos Meletios-Athanasios

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference22 articles.

1. Recent trends of cancer in Europe: A combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s

2. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data

3. Reasons for Improved Survival From Ovarian Cancer in New South Wales, Australia, Between 1980 and 2003

4. Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

5. Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gold Complexes in Anticancer Therapy: From New Design Principles to Particle‐Based Delivery Systems;Angewandte Chemie International Edition;2023-03-15

2. Gold Complexes in Anticancer Therapy: From New Design Principles to Particle‐Based Delivery Systems;Angewandte Chemie;2023-03-15

3. Hyperthermic Intraperitoneal Chemotherapy in the Treatment Armamentarium of Epithelial Ovarian Cancer: Time to End the Dichotomy;Visceral Medicine;2022

4. Surgical and systemic therapies for addressing occult disease in advanced epithelial ovarian cancer;European Journal of Gynaecological Oncology;2022

5. Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer;Expert Opinion on Investigational Drugs;2019-07-30